Gilead Sciences (NASDAQ:GILD) CFO Andrew Dickinson Sells 3,000 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew Dickinson sold 3,000 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $145.29, for a total value of $435,870.00. Following the transaction, the chief financial officer directly owned 164,096 shares in the company, valued at $23,841,507.84. This trade represents a 1.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $147.68 on Thursday. The stock has a market cap of $183.12 billion, a P/E ratio of -55.31 and a beta of 0.33. The firm’s 50-day simple moving average is $139.26 and its 200 day simple moving average is $136.20. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. During the same quarter in the prior year, the firm posted $2.01 EPS. Gilead Sciences’s revenue was up 10.6% compared to the same quarter last year. Equities analysts expect that Gilead Sciences, Inc. will post -0.48 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.

Analyst Ratings Changes

A number of research firms have weighed in on GILD. Zacks Research upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 31st. Truist Financial lowered their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Barclays dropped their price objective on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 29th. Leerink Partners lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Finally, Morgan Stanley decreased their target price on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a research note on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $158.78.

Institutional Trading of Gilead Sciences

A number of large investors have recently added to or reduced their stakes in GILD. Aviva PLC grew its stake in shares of Gilead Sciences by 5.4% during the fourth quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock valued at $141,978,000 after purchasing an additional 59,782 shares during the last quarter. Life Cycle Investment Partners Ltd acquired a new position in Gilead Sciences in the fourth quarter valued at about $1,418,000. Bank of Nova Scotia bought a new position in Gilead Sciences during the second quarter worth about $100,056,000. OMERS ADMINISTRATION Corp bought a new position in Gilead Sciences during the second quarter worth about $55,754,000. Finally, Harvest Fund Management Co. Ltd grew its position in shares of Gilead Sciences by 14.4% during the 4th quarter. Harvest Fund Management Co. Ltd now owns 106,526 shares of the biopharmaceutical company’s stock worth $13,075,000 after buying an additional 13,385 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead expanded six royalty-free voluntary licensing agreements to include its investigational once-yearly lenacapavir formulation for HIV prevention. The agreements cover 120 high-incidence countries and are intended to support technology transfer, manufacturing readiness and future supply. The program could substantially broaden access to Gilead’s HIV-prevention franchise, although the formulation remains investigational. Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
• Positive Sentiment: A new agreement with the Pan American Health Organization will facilitate access to twice-yearly lenacapavir across PAHO member states in Latin America and the Caribbean, adding 14 countries to Gilead’s global access strategy. The deal strengthens the drug’s potential reach and supports long-term demand, though it is primarily an access initiative rather than an immediate earnings catalyst. Gilead and PAHO Announce Milestone Partnership
• Neutral Sentiment: Gilead’s $0.82-per-share dividend went ex-dividend on September 15. The payout supports the income-investment case but can create a mechanical adjustment in the share price on the ex-dividend date. Gilead Sciences Dividend Analysis
• Negative Sentiment: Chief Financial Officer Andrew Dickinson and insider Johanna Mercier each sold 3,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, and each executive retained a substantial holding, limiting the negative signal for investors. CFO Insider Sale Filing

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.